MUSTAFA GÖKHAN ERTOSUN, ÖZLENEN ÖZKAN, ÖMER ÖZKAN
Experimental and Clinical Transplantation - 2021;19(7):723-731
Objectives: Tacrolimus is currently one of the most commonly used immunosuppressant agents to prevent rejection in organ transplant. Although modern immunosuppressive agents have been successful, rejection cannot be completely prevented. Therefore, in organ transplant research, additional treatment methods are being investigated, with the most important one being stem cell therapy. In addition to tacrolimus therapy, stem cell therapy is now clinically applicable, with frequency of concomitant use seeming to expand in the future. In this study, the effects of tacrolimus on stem cells were investigated. Materials and Methods: Adipose derived stem cells were treated with tacrolimus at different doses and time points. We analyzed the effects of changes in stem cell proliferation using MTT analysis. Sox2, Oct3/4, and Nanog protein levels were analyzed by sodium dodecyl sulfate polyacrylamide gel electrophoresis to measure stem cell pluripotency capabilities. Results: Our observations showed that tacrolimus causes changes in stem cell proliferation and pluripotency, with changes dependent on time and dose. Conclusions: The dose of tacrolimus and the time of application of stem cells are important in the planning of stem cell therapy in organ transplant.
